The study has demonstrated that the detection of BRAF mutations in cfDNA is not significantly prognostic in advanced melanoma, and that, provided high LDH patients are excluded from the study population, entering patients by cfDNA analysis into a BRAF+-selected trial will not enrich for a poor prognostic study population. Here, BRAF is linked to melanoma.